Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 12:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 106 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Severe Functional Impairment Clear all

Conditions: Hyperlipidemia, Mixed Dyslipidemia
Interventions: Evolocumab; Biological
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Hepatic Insufficiency, Neoplasms
Interventions: Onureg; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 4
States / cities: Iowa City, Iowa • Detroit, Michigan • Cleveland, Ohio + 1 more

Conditions: Thrombosis
Interventions: BMS-986177; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 3
States / cities: Miami, Florida • Orlando, Florida

Conditions: Diabetes Mellitus, Type 2
Interventions: albiglutide; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 30 Years to 75 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 5
States / cities: Anniston, Alabama • Miami, Florida • Orlando, Florida + 2 more

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 1,342 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Renal Insufficiency
Interventions: Tirofiban; Drug
Lead sponsor: Medicure; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: DeLand, Florida

Conditions: Healthy Volunteer Study, Hepatic Impairment, Renal Impairment
Interventions: Bemnifosbuvir (BEM)/Ruzasvir (RZR) as a fixed-dose combination; Drug
Lead sponsor: Atea Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Orlando, Florida • Tampa, Florida

Conditions: Renal Impairment, Healthy Volunteer
Interventions: BMS-986165; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Depressive Disorder, Major
Interventions: LY2216684; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 3
States / cities: Miami, Florida • Orlando, Florida • San Antonio, Texas

Conditions: Hepatic Impairment
Interventions: Emraclidine; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 3
States / cities: Miami, Florida • Orlando, Florida • San Antonio, Texas

Conditions: Severe Life-limiting COPD, Severe Life-limiting Heart Failure, Severe Life-limiting Cirrhosis, Severe Life-limiting Malignancy, Severe Functional Impairment, End Stage Renal Disease
Interventions: Informed Assent Discussion, Usual Care with Attention Control; Behavioral
Lead sponsor: University of Vermont; Other
Eligibility: 65 Years and older
Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 4
States / cities: Chapel Hill, North Carolina • Charleston, South Carolina • Burlington, Vermont + 1 more

Conditions: Hepatitis B
Interventions: Bepirovirsen; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 3
States / cities: Orlando, Florida • Tampa, Florida • San Antonio, Texas

Conditions: Multiple Myeloma, Advanced Solid Tumors
Interventions: Ixazomib; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 10
States / cities: Atlanta, Georgia • Peoria, Illinois • Fairway, Kansas + 7 more

Conditions: Hepatic Impairment
Interventions: Iptacopan; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Kidney Failure, Chronic, Healthy Volunteers, Renal Impairment
Interventions: BMS-986278; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 84 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 4
States / cities: Miami, Florida • Orlando, Florida

Conditions: Healthy, Hepatic Insufficiency
Interventions: LY3502970; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 4
States / cities: Miami, Florida • Orlando, Florida • San Antonio, Texas

Conditions: Hepatic Impairment
Interventions: Elacestrant dihydrochloride; Drug
Lead sponsor: Stemline Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 3
States / cities: Yucaipa, California • Miami, Florida • San Antonio, Texas

Conditions: Post Traumatic Stress Disorder
Interventions: 3,4-methylenedioxymethamphetamine, d-amphetamine, Therapy; Drug · Behavioral
Lead sponsor: Stephen Robert Marder; Federal
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Los Angeles, California

Conditions: Hepatitis C Virus
Interventions: Velpatasvir; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 4
States / cities: Miami, Florida • Orlando, Florida • Saint Paul, Minnesota + 1 more

Conditions: Renal Impairment
Interventions: ESK-001; Drug
Lead sponsor: Alumis Inc; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 4
States / cities: Miami, Florida • Miami Lakes, Florida • Orlando, Florida

Conditions: Renal Insufficiency
Interventions: Lanabecestat, Iohexol; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 35 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 3
States / cities: Tustin, California • Miami, Florida • Orlando, Florida

Conditions: Hepatic Impairment, Hepatic Function
Interventions: Lenvatinib; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 5
States / cities: Miami, Florida • Orlando, Florida • Minneapolis, Minnesota + 1 more

Conditions: Chronic Hepatitis C
Interventions: GS-5816; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 5
States / cities: Miami, Florida • Orlando, Florida • San Antonio, Texas

Conditions: Renal Impairment
Interventions: varespladib methyl; Drug
Lead sponsor: Anthera Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 3
States / cities: Orlando, Florida • Minneapolis, Minnesota • Knoxville, Tennessee

Search by objective public record fields.

Estimation Study to Assess the Effect of Severe Renal Impairment and End-stage Renal Disease Hemodialysis on the Pharmacokinetics of Evolocumab

A Study to Evaluate CC-486/Onureg in Participants With Moderate or Severe Hepatic Impairment Compared With Normal Hepatic Function in Participants With Myeloid Malignancies

Evaluate Pharmacokinetics and Safety of BMS-986177 in Participants With Normal Renal Function and With Moderate or Severe Renal Impairment

A Study of the Pharmacokinetics of Albiglutide in Normal and Renally Impaired Subjects.

A Study to Learn About the Relationship Between Hepatic Impairment and Myelosuppression (Decreased Bone Marrow Function) in Breast Cancer Patients Treated With the Study Medicine Palbociclib (Pal-bow-sai-klib)

Pharmacokinetic Evaluation of Tirofiban Using a Single High-Dose Bolus In Subjects With Varying Degrees of Renal Function

Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function

A Study to Assess the Safety of Experimental Medication BMS986165 in Participants With Normal Kidney Function and Participants With Mild to End-Stage Kidney Disease.

A Study of LY2216684 in Participants With Impaired Hepatic Function

A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Emraclidine

Communication During Hospitalization About Resuscitation Trial

A Study to Evaluate Blood Levels of Bepirovirsen in Adult Participants With Severe or Moderate Kidney Disease

Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Participants With Normal Renal Function or Severe Renal Impairment

Pharmacokinetic (PK) and Safety Study of Iptacopan (LNP023) in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Matched Control Healthy Participants With Normal Hepatic Function.

A Study to Evaluate BMS-986278 in Participants With Normal Renal Function, Severe Renal Impairment, or End-Stage Renal Disease on Intermittent Hemodialysis

A Study of LY3502970 in Participants With Impaired and Normal Liver Function

A PK Study Testing Single Oral Dose of Elacestrant in Subjects With Normal or Severely Impaired Hepatic Function

MDMA-Assisted Therapy for Veterans With Moderate to Severe Post Traumatic Stress Disorder

Study to Evaluate the Pharmacokinetics of Velpatasvir in Participants With Normal Renal Function and Severe Renal Impairment

An Investigational Study of ESK-001 in Participants With Normal Renal Function and Participants With Mild, Moderate, and Severe Impaired Renal Function

A Study of Lanabecestat in Participants With Severe Kidney Impairment Compared to Healthy Participants

A Pharmacokinetic and Safety Study of E7080 in Subjects With Mild (10 mg), Moderate (10 mg), and Severe Hepatic Impairment (5 mg) and Normal Hepatic Function (10 mg)

A Phase 1 Study to Evaluate the Pharmacokinetics of GS-5816 in Subjects With Normal Hepatic Function and Moderate or Severe Hepatic Impairment

A Study of the Pharmacokinetics and Safety of Varespladib in Subjects With Normal or Impaired Renal Function